<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01507337</url>
  </required_header>
  <id_info>
    <org_study_id>NN2211-1327</org_study_id>
    <nct_id>NCT01507337</nct_id>
  </id_info>
  <brief_title>Comparison of the Effect of Liraglutide in Young Versus Elderly Healthy Volunteers</brief_title>
  <official_title>An Open Label, Single Dose Trial With Two Groups Comparing the Pharmacokinetics of Liraglutide in Young Versus Elderly Healthy Subjects of Both Sexes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of this trial is to compare the exposure of&#xD;
      liraglutide in young versus elderly healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">June 2004</completion_date>
  <primary_completion_date type="Actual">June 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the liraglutide plasma concentration time curve (AUC 0-t)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the liraglutide plasma concentration time curve (AUC 0-infinity)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax, maximum liraglutide plasma concentration</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax, time to reach Cmax</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tÂ½, terminal plasma elimination half-life</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Diabetes</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Elderly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Young</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <description>A single dose of 1 mg administered subcutaneously (under the skin)</description>
    <arm_group_label>Elderly</arm_group_label>
    <arm_group_label>Young</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Good general health as judged by the investigator, based on medical history, physical&#xD;
             examination including 12-lead ECG (electrocardiogram), vital signs, and blood and&#xD;
             urinary laboratory assessments&#xD;
&#xD;
          -  Age, young subjects: age 18-45 years (both incl.)&#xD;
&#xD;
          -  Age, elderly subjects: age at least 65 years&#xD;
&#xD;
          -  Body Mass Index (BMI) 18-30 kg/m^2 (both incl.)&#xD;
&#xD;
          -  Blood pressure, young: Diastolic 50-90 mmHg, systolic 90-140 mmHg&#xD;
&#xD;
          -  Blood pressure, elderly: Diastolic 50-95 mmHg, systolic 92-160 mmHg&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of any clinically significant renal, hepatic, cardiovascular, pulmonary,&#xD;
             gastrointestinal, metabolic, endocrine, haematological, neurological, psychiatric&#xD;
             disease, or other major disorders that could interfere with the objectives of the&#xD;
             trial, as judged by the investigator&#xD;
&#xD;
          -  Impaired renal function&#xD;
&#xD;
          -  Any clinically significant abnormal ECG (electrocardiogram)&#xD;
&#xD;
          -  Active hepatitis B and/or active hepatitis C&#xD;
&#xD;
          -  Positive HIV (human immunodeficiency virus) antibodies&#xD;
&#xD;
          -  Febrile illness within 5 days prior to first administration of liraglutide&#xD;
&#xD;
          -  History of alcoholism or drug abuse during the last 12 months&#xD;
&#xD;
          -  Smoking of more than 10 cigarettes per day, or the equivalent for other tobacco&#xD;
             products&#xD;
&#xD;
          -  Habitual excessive consumption of methylxanthine-containing beverages and foods&#xD;
             (coffee, tea, soft drinks such as cola, chocolate) as judged by the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <results_reference>
    <citation>Damholt B, Golor G, Wierich W, Pedersen P, Ekblom M, Zdravkovic M. An open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily glucagon-like peptide-1 analogue liraglutide. J Clin Pharmacol. 2006 Jun;46(6):635-41.</citation>
    <PMID>16707410</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>January 6, 2012</study_first_submitted>
  <study_first_submitted_qc>January 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2012</study_first_posted>
  <last_update_submitted>January 23, 2017</last_update_submitted>
  <last_update_submitted_qc>January 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

